Abstract
Background:
Prenatal screening for chromosomal aneuploidies was initiated in the 1970s,
based in maternal age. With the introduction of serum and ultrasound biomarkers, new screening
methodologies, with higher detection rates and lower false-positive rates, were implemented. More
recently, cell-free fetal DNA testing was presented as a non-invasive test that uses maternal plasma
to obtain fetal DNA in order to search for fetal aneuploidies or other chromosomal imbalances.